Education
About Us
Working with TipRanks
Follow Us
Enanta Pharmaceuticals (ENTA)
NASDAQ:ENTA
Total Valuation
Enanta Pharmaceuticals has a market cap or net worth of $153.70M. The enterprise value is $124.00M.
Market Cap$153.70M
Enterprise Value$124.00M
Share Statistics
Enanta Pharmaceuticals has 21,376,581 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding21,376,581
Owned by Insiders6.73%
Owned by Institutions27.67%
Financial Efficiency
Enanta Pharmaceuticals’s return on equity (ROE) is -0.90 and return on invested capital (ROIC) is -37.39%.
Return on Equity (ROE)-0.90
Return on Assets (ROA)-0.31
Return on Invested Capital (ROIC)-37.39%
Return on Capital Employed (ROCE)-0.38
Revenue Per Employee516.30K
Profits Per Employee-885.84K
Employee Count131
Asset Turnover0.18
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Enanta Pharmaceuticals is -1.89. Enanta Pharmaceuticals’s PEG ratio is -0.16.
PE Ratio-1.89
PS Ratio0.00
PB Ratio1.34
Price to Fair Value1.70
Price to FCF-1.53
Price to Operating Cash Flow-2.26
PEG Ratio-0.16
Income Statement
In the last 12 months, Enanta Pharmaceuticals had revenue of 67.64M and earned -116.05M in profits. Earnings per share was -5.48.
Revenue67.64M
Gross Profit67.64M
Operating Income-121.69M
Pretax Income-117.79M
Net Income-116.05M
EBITDA-104.51M
Earnings Per Share (EPS)-5.48
Cash Flow
In the last 12 months, operating cash flow was -55.46M and capital expenditures -26.78M, giving a free cash flow of -82.24M billion.
Operating Cash Flow-55.46M
Free Cash Flow-82.24M
Free Cash Flow per Share-3.85
Dividends & Yields
Enanta Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.49
52-Week Price Change-42.50%
50-Day Moving Average5.55
200-Day Moving Average7.98
Relative Strength Index (RSI)71.03
Average Volume (3m)131.59K
Important Dates
Enanta Pharmaceuticals upcoming earnings date is Aug 11, 2025, TBA Not Confirmed.
Last Earnings DateMay 12, 2025
Next Earnings DateAug 11, 2025
Ex-Dividend Date―
Financial Position
Enanta Pharmaceuticals as a current ratio of 5.21, with Debt / Equity ratio of 62.79%
Current Ratio5.21
Quick Ratio5.21
Debt to Market Cap0.00
Net Debt to EBITDA-0.17
Interest Coverage Ratio-11.12
Taxes
In the past 12 months, Enanta Pharmaceuticals has paid -1.74M in taxes.
Income Tax-1.74M
Effective Tax Rate0.01
Enterprise Valuation
Enanta Pharmaceuticals EV to EBITDA ratio is -2.27, with an EV/FCF ratio of -2.45.
EV to Sales3.51
EV to EBITDA-2.27
EV to Free Cash Flow-2.45
EV to Operating Cash Flow-3.01
Balance Sheet
Enanta Pharmaceuticals has $193.38M in cash and marketable securities with $58.73M in debt, giving a net cash position of -$134.64M billion.
Cash & Marketable Securities$193.38M
Total Debt$58.73M
Net Cash-$134.64M
Net Cash Per Share-$6.30
Tangible Book Value Per Share$6.09
Margins
Gross margin is 100.00%, with operating margin of -179.92%, and net profit margin of -171.58%.
Gross Margin100.00%
Operating Margin-179.92%
Pretax Margin-174.15%
Net Profit Margin-171.58%
EBITDA Margin-154.52%
EBIT Margin-157.98%
Analyst Forecast
The average price target for Enanta Pharmaceuticals is $17.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$17.00
Price Target Upside139.10% Upside
Analyst ConsensusModerate Buy
Analyst Count3
Revenue Growth Forecast-11.55%
EPS Growth Forecast27.32%